



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/809,638	03/14/2001	Mary Faris	G&C 129.35-US-01	5083

36327 7590 10/04/2004

AGENSYS C/O MORRISON & FOERSTER LLP
3811 VALLEY CENTRE DRIVE, SUITE 500
SAN DIEGO, CA 92130

EXAMINER

HARRIS, ALANA M

ART UNIT PAPER NUMBER

1642

DATE MAILED: 10/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.	FARIS ET AL.	
Examiner Alana M. Harris, Ph.D.	Art Unit 1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 14 June 2004.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,14 and 23 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,14 and 23 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. 09282004.

5) Notice of Informal Patent Application (PTO-152)
6) Other: _____.

DETAILED ACTION

1. The finality of the action mailed May 19, 2004 has been withdrawn and PROSECUTION IS HEREBY REOPENED. A new action is set forth below.

2. Claims 1, 14 and 23 are pending.

Claim 7 has been cancelled.

Claims 14 and 23 have been amended.

Claims 1, 14 and 23 are examined on the merits.

Withdrawn Rejections

Claim Rejections - 35 USC § 112

3. The rejection of claims 14 and 23 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention is withdrawn. Claim 7 has been cancelled.

4. The rejection of claims 14 and 23 under 35 U.S.C. 112, first paragraph, because the specification, does not reasonably provide enablement commensurate with the scope of the claimed invention is withdrawn. Claim 7 has been cancelled.

New Grounds of Rejection

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

6. Claims 2, 14 and 23 are rejected under 35 U.S.C. 102(e) as being anticipated by WO200270539 A2 (filed March 5, 2002/ IDS reference 2, April 15, 2001). WO200270539 discloses sequence 1397, an amino acid sequence that is the same as Applicants' SEQ ID NO: 2, see the three attached database sheets. The isolated 125P5C8 protein (SEQ ID NO: 2) encoded by a 125P5C8 nucleotide, where T can be U comprises a polynucleotide of at least 10 bases of Figure 2 (SEQ ID NO: 1) that comprises the base at position 2065. Absent evidence to the contrary the disclosed polynucleotide that encodes a 125P5C8

protein identified as SEQ ID NO: 2 is contained in the plasmid designated

Escherichia coli DH5A 125P5C8PRO deposited with American Type Culture

Collection as Accession No. PTA-3137.

Double Patenting

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Claims 1, 14 and 23 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 12-17, 19, 21, 26, 51 and 52 of copending Application No. 10/099,460 (filed March 13, 2002). Although the conflicting claims are not identical, they are not patentably distinct from each other because SEQ ID NO: 2 of the instant application is 100% identical to SEQ ID NO: 3 and SEQ ID NO: 13 of the copending application reading on claim 1 of the copending application, 10/099,460 and intrinsically possessing all the attributes of the sequence disclosed in '460. Furthermore, SEQ ID NO: 1 of the instant application is

the same as copending application's '460 nucleic acid sequence identified as SEQ ID NO: 12.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

9. Claims 1, 14 and 23 directed to an invention not patentably distinct from claims 1, 12-17, 19, 21, 26, 51 and 52 of commonly assigned co-pending application 10/099,460 (filed March 13, 2002). Specifically, both sets of claims read on identical nucleotide sequences and the encoded polypeptide sequence.

10. The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP § 2302). Commonly assigned 10/099,460 (filed March 13, 2002), discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(e), (f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee can, under 35 U.S.C. 103(c) and 37 CFR 1.78(c), either show that the conflicting inventions were commonly owned at the time the invention in this application was made, or name the prior inventor of the conflicting subject matter.

A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon

the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications filed on or after November 29, 1999.

DIS	2283	INC	2285
RESULT	2		
ID	A3Z11567		
ID	ABZ11567 standard; cDNA; 2479 BP.		
XC			
XC	ABZ11567;		
AC			
XX	20-JUN-2003 (first entry)		
XX	DIT		
XX	XX		
D3	Human polynucleotide SEQ ID NO 449.		
CC			
KU	Human; genome mapping; gene therapy; food supplement; virus; fungus;		
KW	cell-proliferative disorder; Alzheimer; neurodegenerative disease; bacterial;		
KW	Parkinson's disease; Alzheimer's disease; autoimmune disease; multiple sclerosis; diabetes; genetic disorder; infection;		
KW	arthritis; cytostatic; immunomodulator; nootropic; neuroprotective;		
KW	antibarkinsonian; antidiabetic; immunosuppressive; dermatological;		
KW	haemostatic; vulnerary; fungicide; antibacterial; virucide; protozoicide;		
KW	antiarthritic; gene; ss.		
XX	Homo sapiens.		
XX			
XX			
PN	WO200270539-A2.		
XX			
PD	12-SEP-2002.		
XX			
PP	05-MAR-2002; 2002WO-US005095.		
XX			
PR	05-MAR-2001; 2001US-00799451.		
XX			
PA	(HYSEQ-) HYSEQ INC.		
XX			
PI	Tang YT, Zhou P, Goodrich RW, Asundi V, Zhang J, Zhao QA, Ren P;		
PI	Xue AJ, Yang Y, Ma J, Yamazaki Y, Chen R, Wang Z, Ghosh M;		
PI	Wehrman T, Wang J, Wang D, Drmanac RT;		
XX			
XX	WPI: 2002-759812/82.		
DR	P-PSDB; ABP693550.		
XX			
PS			
PT	New polynucleotides comprising sequences assembled from expressed		
PT	sequence tags (ESTs), useful for treating cell-proliferative,		
PT	neurodegenerative, autoimmune, genetic, myeloid or lymphoid, or platelet		
PT	or coagulation disorders.		
XX			
XX			
CC	Claim 1: SEQ ID NO 449; 1012PP + Sequence Listing; English.		
CC			
CC	The invention relates to an isolated polynucleotide (1) comprising a		
CC	nucleotide sequence selected from any of 948 sequences (ABZ1119-		
CC	ABZ12066) or their mature protein coding portion, active domain coding		
CC	protein or complementary sequences. The polynucleotides are useful for		
CC	identifying expressed genes or for physical mapping of human genome. The		
CC	encoded polypeptides (ABP68102-ABP6949) are useful as molecular weight		
CC	markers, as a food supplement, for generating antibodies, in medical		
CC	imaging, screening and diagnostic assays and for treating cell-		
CC	proliferative disorders (cancer), neurodegenerative diseases (Parkinson's		
CC	or Alzheimer's disease), autoimmune diseases (multiple sclerosis,		
CC	diabetes, lupus), genetic disorders, myeloid or lymphoid disorders,		
CC	platelet or coagulation disorders, wound, burns, incision, ulcers, liver		
CC	or lung fibrosis, infections (bacterial, viral, fungal, parasitic),		
CC	arthritis, etc. Note: The sequence data for this patent did not form part		
CC	of the printed specification, but was obtained in electronic format		
CC	directly from WIPO at ftp.wipo.int/pub/published_pct_sequences		
XX			
SC	Sequence 2479 BP; 684 A; 517 C; 606 G; 672 T; 0 U; 0 Other;		
Query	99.8%	Score	2099 B; DB 6; Length 2479;
Match	Best Local Similarity	99.9%	Pred. No. 0;
Matches	Matches 2101; Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
CC	1 ATGACCTCGCTGAGAGAATCTCTGGAGTCGCTGGATGATGTTCTGGCT 60		

Db	Q1	1263 GGCCTGATATGCTTACAGAAGAAATATGAACTTTCTGGGCT 1320
Q1	1141 AGCTTAAAGTCTTCAGAAGAAATATGAACTTTCTGGGCT 1200	
Db	1323 AGTCTTAAAGTCTTCAGAAGAAATATGAACTTTCTGGGCT 1382	
Q1	1201 GTTGGTGTGTTGTTGGTGTGGATAGCTAGCTGGCTAAGAACTGGGC 1260	
Db	1383 GTTGGTGTGTTGGATAGCTAGCTGGCTAAGAACTGGGC 1442	
Q1	1261 AATGGGACCAAGAGGGTCTCTCTCCATGGCTTGGGATGAC 1320	
Db	1503 AATGGGACCAAGAGGGTCTCTCTCCATGGCTTGGGATGAC 1502	
Q1	1443 AATGGGACCAAGAGGGTCTCTCTCCATGGCTTGGGATGAC 1502	
Q1	1321 AATGAGGGTGTGTTGAGCTAGAAGATCGTCATCTGCTAATGAAAGCTGGGAC 1380	
Db	1503 AATGAGGGTGTGTTGAGCTAGAAGATCGTCATCTGCTAATGAAAGCTGGGAC 1562	
Q1	1381 TTCTAACTATTTGAGAGTGTGCTTAAGCCCTATATGGGAACTGACTAAC 1440	
Db	1563 TTCTAACTATTTGAGAGTGTGCTTAAGCCCTATATGGGAACTGACTAAC 1622	
Q1	1441 ATGGGCTAGGGAAAGTGGTTCTATACAGCTTGGCTCAGAACAGGTTCAC 1440	
Db	1623 ATGGGCTAGGGAAAGTGGTTCTATACAGCTTGGCTCAGAACAGGTTCAC 1682	
Q1	1501 ACTTGGGAAATATGCTTGTGAACTACCAATTGGAACTTGGCTAACCTCTT 1560	
Db	1683 ACTTGGGAAATATGCTTGTGAACTACCAATTGGCTAACCTCTT 1742	
Q1	1561 CGGTGACCAAGAGGGAGAGTCGCAACGCACTTACATGACCTTACATTGGCGAC 1620	
Db	1743 CGGTGACCAAGAGGGAGAGTCGCAACGCACTTACATGACCTTACATTGGCGAC 1802	
Q1	1621 CTGGTGGATTGTTGTCACACTTGGGACCAAGAGGACTCTGGAGAAACTG 1680	
Db	1803 CTGGTGGATTGTTGTCACACTTGGGACCAAGAGGACTCTGGAGAAACTG 1862	
Q1	1681 CAGCTTATGCTGTTGAACTCTGAAAGAGCTTAATCACTGATATTCTGGG 1740	
Db	1863 CAGCTTATGCTGTTGAACTCTGAAAGAGCTTAATCACTGATATTCTGGG 1922	
Q1	1741 TATTCACCTGACCTGCTCTGGAGATATCTACCTCTGACACGGCTG 1800	
Db	1923 TATTCACCTGACCTGCTCTGGAGATATCTACCTCTGACACGGCTG 1982	
Q1	1801 AAGGTTACACAGCTGTCAGATGTTGAACTTTATGAGGCTG 1860	
Db	1983 AAGGTTACACAGCTGTCAGATGTTGAACTTTATGAGGCTG 2042	
Q1	1861 ATCAAGTTGGTTACGACAACTCCAGCTGACTGAGTGTCTGAAATTCTGGT 1920	
Db	2043 ATCAAGTTGGTTACGACAACTCCAGCTGACTGAGTGTCTGAAATTCTGGT 2102	
Q1	1921 GCAAGATTAGGATCTGAACTCTGACCCACTAATAGAGCAACGAGAGCTGATA 1980	
Db	2103 GCAAGATTAGGATCTGAACTCTGACCCACTAATAGAGCAACGAGAGCTGATA 2162	
Q1	1981 GACCCAGAGAGTTCTGAGAATTCATTTCTGGATGTTGACCTACAGAA 2040	
Db	2163 GACCCAGAGAGTTCTGAGAATTCATTTCTGGATGTTGACCTACAGAA 2222	
Q1	2041 GCAACAGTTGAAACACCATTTCTGAACTTGTGAACTCTGGCTA 2100	
Db	2223 GCAACAGTTGAAACACCATTTCTGAACTTGTGAACTCTGGCTA 2282	
CY	2101 AAC 2103	
Db	2283 AAC 2285	

ALIGNMENTS

Abm70704	Photorhabdus
Abm33100	Acinetobacter
Abm26672	Human
Abm31622	599
Abm31622	Protein e
Abj25677	Aspergillus
Abj24105	Protein e
Abm32096	Protein e
Abm39087	Herbicide
Abm38788	Neisseria
Abm5786	Human
Abm5786	agu
Abm94322	Human
Abp58050	Human
Abp58050	agu
Abg58056	Arabidopsis
Abg59437	Arabidopsis
Abg59184	Arabidopsis
Abg58055	Arabidopsis
Abg59436	Arabidopsis
Abg640118	Human
Abg65311	NOV
Abu34347	Human
Abu34347	pro
Abu34347	Protein e

DT - 20-JAN-2003 (first entry)
XX
DE Human polypeptide SEQ ID NO 1397.
XX

KW cell-proliferative disease; gene therapy; food supplement; virus; fungicidal; human; genome mapping; gene therapy; food supplement; virus; fungicidal; parkinson's disease; Alzheimer's disease; autoimmune disease; multiple sclerosis; diabetes; genetic disorder; wound; burn; infection; arthritis; cytostatic; immunomodulator; nootropic; neuroprotective; antiparkinsonian; antidiabetic; immunosuppressive; dermatological; haemostatic; vulnerary; fungicide; antibacterial; viricide; protozoacide; antihistaminic.

OS Homo sapiens.
XX WO200270539-A2.
PN 12-SEP-2002.
XX
PD

PF 05-MAR-2002; 2002WO-05005095.
XX
PR 05-MAR-2001; 2001US-00799451.

PA (HSE-) HYSEG INC.

1882 BUELL 13

Lang J, Xiong F, Gao L, Chen K, Aslund V, Wang Xue AU, Yang Y, Ma Y, Yamazaki V, Chen R, Wann Wehrman T, Wang J, Wang D, Drmanac RT, xx

PT New polynucleotides comprising sequences assembled from expressed sequence tags (ESTs), useful for treating cell-proliferative, PT neurodegenerative, autoimmune, genetic, myeloid or lymphoid, or plate-

PT or coagulation disorders.

Claim 9; S3Q ID NO 1397; 1012PP + Sequence Listing; English.

CC The invention relates to an isolated polynucleotide (1) comprising a nucleotide sequence selected from any of 948 sequences (ABZ1119-11).

Application/Control Number: 09/809,638

Art Unit: 1642

CC protein or complementary sequences. The polynucleotides are useful for
 CC identifying expressed genes or for physical mapping of human genome. The
 CC encoded polypeptides (ABP6902; ABP6849) are useful as molecular weight
 CC markers, as a food supplement for generating antibodies in medical
 CC imaging, screening and diagnostic assays and for treating cell-
 CC proliferative disorders (cancer), neurodegenerative diseases (Parkinson's
 CC or Alzheimer's disease), autoimmune diseases (multiple sclerosis,
 CC diabetes, lupus) generic disorders, myeloid or lymphoid disorders,
 CC platelet or coagulation disorders, wound, burns, incision, ulcers, liver
 CC or lung fibrosis, infections (bacterial, viral, fungal, parasitic), liver
 CC arthritis, etc. Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic format
 CC directly from WIPO at ftp://wipo.int/pub/published_Pct-sequences

XX

SQ Sequence 699 AA;

Query	Match	Score	DB	Length	Start	End
QY	100.0%	3720	5	699	1	699
Db	Best Local Similarity	100.0%	Pred. No.	0	Matches	0
Db	Matches	699	Conservative	0	Mismatches	0
QY	1	MTSLWREILLESILGCVNSLMDLGKMYIPFQLETLTQLEGSIATSPFLITTP 60	1	MTSLWREILLESILGCVNSLMDLGKMYIPFQLETLTQLEGSIATSPFLITTP 60		
Db	61	WKLJWIKKKGMLTURITIGSIAFOANAKALMVLALGSSSLIVORTWMSHORY 120	61	WKLJWIKKKGMLTURITIGSIAFOANAKALMVLALGSSSLIVORTWMSHORY 120		
QY	121	LRINGFILGQVNLRTWTSIAPINSYQSNRVLVLTIAITDRIGDGCSKEEK 180	121	LRINGFILGQVNLRTWTSIAPINSYQSNRVLVLTIAITDRIGDGCSKEEK 180		
Db	181	KIGEVATGMSRNPNTLACRAPSILVTHNFGESLWSRVAASGPFRGPANPFGCA 240	181	KIGEVATGMSRNPNTLACRAPSILVTHNFGESLWSRVAASGPFRGPANPFGCA 240		
Db	241	VLLCLASGLMLPSLWFRGTLIWWVOTASANGLILHTWANSGCVPATASHMPO 300	241	VLLCLASGLMLPSLWFRGTLIWWVOTASANGLILHTWANSGCVPATASHMPO 300		
Db	301	TIGHINGSTNGKTMIAFMILEPFCANCATKAVPGQVARESDVLLGTMILL 360	301	TIGHINGSTNGKTMIAFMILEPFCANCATKAVPGQVARESDVLLGTMILL 360		
Db	361	GLANLPGPKNDLQLOOTSSKULPKSEKNGKJLWLLVQGLSLGRHAKYERLIG 420	361	GLANLPGPKNDLQLOOTSSKULPKSEKNGKJLWLLVQGLSLGRHAKYERLIG 420		
QY	421	KVAPKTKVSAIWFRECGNEGMSLRSBHLNETGADDTILLESASKPMPGNDLT 480	421	KVAPKTKVSAIWFRECGNEGMSLRSBHLNETGADDTILLESASKPMPGNDLT 480		
Db	481	MLGKLGPTDPRSTRTHGIMALSRPVTKSHLRSPECIAPIAIIILTMNSK 540	481	MLGKLGPTDPRSTRTHGIMALSRPVTKSHLRSPECIAPIAIIILTMNSK 540		
QY	541	LDFPVTHTSEHEDDLDKQIAAVSKLXKSSSNQVFLGTTSPGCSRMLTTERENY 600	541	LDFPVTHTSEHEDDLDKQIAAVSKLXKSSSNQVFLGTTSPGCSRMLTTERENY 600		
Db	601	KDIDSTDHDRWCEYIMRGLIRQYARSHAEELDSIQMKFRPDPPTNPNQKVI 660	601	KDIDSTDHDRWCEYIMRGLIRQYARSHAEELDSIQMKFRPDPPTNPNQKVI 660		
QY	661	DHRESEKHNPREGSYKGCHYVNEHFMHPTPKYL 699	661	DHRESEKHNPREGSYKGCHYVNEHFMHPTPKYL 699		
Db	661	DHRESEKHNPREGSYKGCHYVNEHFMHPTPKYL 699	661	DHRESEKHNPREGSYKGCHYVNEHFMHPTPKYL 699		

Art Unit: 1642

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571)272-0831. The examiner works a flexible schedule, however she can normally be reached between the hours of 6:30 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Alana M. Harris, Ph.D.
28 September 2004

AMHarris
ALANA M. HARRIS, PH.D.
PRIMARY EXAMINER
9/28/2004